泊马度胺治疗伴或不伴HIV感染的 symptomatic 卡波西肉瘤:一项I/II期研究
这项I/II期研究评估口服泊马度胺治疗 symptomatic 卡波西肉瘤(KS)的耐受性、药代动力学和活性。22例患者(15例HIV感染,17例晚期T1疾病,19例既往接受过KS治疗)接受5 mg每日一次治疗,16例(73%)缓解,HIV感染组缓解率60%,HIV未感染组100%。泊马度胺耐受良好且具有活性,与HIV状态无关,缓解迅速并改善自我报告结局。
要点
- 泊马度胺5 mg每日一次在 symptomatic KS 中耐受良好,未发生剂量限制性毒性。
- 总缓解率73%(95%CI 50%-89%),HIV感染组60%,HIV未感染组100%。
- 中位缓解时间4周,治疗期间健康相关生活质量无损害,外观满意度改善(P=.03)。
核心结论
- 泊马度胺在卡波西肉瘤中耐受良好且具有活性,无论HIV状态如何。
- 缓解迅速,自我报告结局改善,且发生于晚期和经重度预处理疾病。
- 相关性研究至少部分支持免疫学活性机制。
研究设计与样本
- I/II期研究,评估口服泊马度胺在 symptomatic 卡波西肉瘤患者中的耐受性、药代动力学和活性。
- 初始剂量水平为5 mg每日一次,每28天周期用药21天,若不可耐受则降级至3 mg,并给予阿司匹林81 mg每日一次血栓预防。
- HIV感染者要求病毒血症控制,且经3个月抗逆转录病毒治疗(ART)后KS持续存在或经2个月ART后KS进展。
- 共治疗22例患者;15例(68%)HIV感染,17例(77%)为晚期(T1)疾病,19例(86%)既往接受过除ART外的KS治疗。
主要发现
- 所有患者均接受5 mg治疗,因未发生剂量限制性毒性。
- 共156个周期,可能归因于治疗的3/4级不良事件为中性粒细胞减少(23个周期,10例患者)、感染(1个周期)和水肿(1个周期)。
- 16例患者缓解(73%;95%CI 50%-89%):HIV感染组15例中9例缓解(60%;95%CI 32%-84%),HIV未感染组7例全部缓解(100%;95%CI 59%-100%)。
- 中位缓解时间为4周(范围4-36周)。
- 健康相关生活质量在治疗期间无损害,治疗结束时外观满意度改善(P=.03)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma-associated herpesvirus. Unmet needs include therapies that are oral, anthracycline sparing, and deliverable in resource-limited settings. We evaluated pomalidomide, an oral immune modulatory agent, in patients with symptomatic KS. Methods The primary objectives were to assess tolerability, pharmacokinetics, and activity. Initial dosage level was 5 mg once per day for 21 days per 28-day cycle, with a de-escalated level of 3 mg if not tolerable, and aspirin 81 mg once per day thromboprophylaxis. HIV-infected patients required controlled viremia with either persistent KS despite 3 months of antiretroviral therapy (ART) or progressive KS despite 2 months of ART. Evaluations included tumor response and health-related quality of life (HRQL). Results Twenty-two patients were treated; 15 (68%) were HIV infected, 17 (77%) had advanced (T1) disease, and 19 (86%) previous KS therapy excluding ART. All were treated with 5 mg because no dose-limiting toxicities occurred. Over 156 cycles, the grade 3/4 adverse events possibly attributable to therapy were neutropenia (23 cycles, 10 patients), infection (1 cycle), and edema (1 cycle). Sixteen patients responded (73%; 95% CI, 50% to 89%): nine of 15 HIV-infected patients (60%; 95% CI, 32% to 84%) and all seven HIV-uninfected patients (100%; 95% CI, 59% to 100%). Median time to response was 4 weeks (range, 4 to 36 weeks). HRQL showed no impairment during therapy and improved satisfaction with appearance at end therapy ( P = .03). Significant increases in CD4+ and CD8+ cells were seen in patients with and without HIV, together with a transient increase in Kaposi's sarcoma-associated herpesvirus viral load at week 4 ( P = .05). Conclusion Pomalidomide is well tolerated and active in KS regardless of HIV status. Responses were rapid, with improved self-reported outcomes, and occurred in advanced and heavily pretreated disease. Correlative studies support, at least in part, an immunologic mechanism of activity.
引用
- Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. J Clin Oncol. 2016. PMID: 27863194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。